Saturday, May 25, 2013 Last update: 8:34 AM
Company Tech News as it Breaks
Trade Events
Amarantus BioSciences, Inc.
News articles for Amarantus BioSciences, Inc.:
Tuesday, November 27, 2012
- Amarantus BioSciences Announces Positive Data for MANF in Delivery Diffusion Animal Model of Parkinson's DiseaseSUNNYVALE, Calif., Nov. 27, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has successfully completed experiments demonstrating that ... read more
Monday, November 26, 2012
- Amarantus BioSciences Demands Cessation of Unauthorized Listing on Berlin-Bremen Stock ExchangeSUNNYVALE, Calif., Nov. 26, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, announced today, with the assistance of its Manhattan-based corporate counsel at JS ... read more